Transplantation of Dopamine Neurons: Extent and Mechanisms of Functional Recovery in Rodent Models of Parkinson's Disease

Dopamine Handbook

Volumn , Issue , 2010, Pages

  Dunnett, Stephen B ^a   Björklund, Anders ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Dopamine neurons; Parkinson's disease; Transplantation

Indexed keywords

EID: 84918862063     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195373035.003.0032     Document Type: Chapter

References (233)

1. Olson L, Seiger Å. Brain tissue transplanted to the anterior chamber of the eye. 1. Fluorescence histochemistry of immature catecholamine and 5-hydroxytryptamine neurons innervating the iris. Z Zellforsch. 1972;195: 175-194.
2. Björklund A, Stenevi U, Svendgaard N-A. Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path. Nature. 1976;262: 787-790.
3. Stenevi U, Björklund A, Svendgaard N-A. Transplantation of central and peripheral monoamine neurons to the adult rat brain: techniques and conditions for survival. Brain Re.s 1976;114: 1-20.
4. Perlow MJ, Freed WJ, Hoffer BJ, Seiger Å, Olson L, Wyatt RJ. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science. 1979;204: 643-647.
5. Björklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral transplants. Brain Res. 1979;177: 555-560.
6. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol. 1968;5: 107-110.
7. Schwarting RKW, Huston JP. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol. 1996;49: 215-266.
8. Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30: 194-202.
9. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970;24: 485-493.
10. Schwarting RKW, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol. 1996;50: 275-331.
11. Dunnett SB. Motor functions of the nigrostriatal dopamine system: studies of lesions and behaviour. In: Dunnett SB, Bentivoglio M, Björklund A, Hökfelt T, eds. Handbook of Chemical Neuroanatomy. Vol. 21. Dopamine. Amsterdam: Elsevier; 2005;235-299.
12. Dunnett SB, Björklund A. Parkinson's disease: prospects for novel restorative and neuroprotective treatments. Nature Suppl. 1999;399: 32-39.
13. Kirik D, Rosenblad C, Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol. 1998;152: 259-277.
14. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990;13: 290-296.
15. Olson L, Seiger Å, Strömberg I. Intraocular transplantation in rodents: a detailed account of the procedure and examples of its use in neurobiology with special reference to brain tissue grafting. Adv Cell Neurobiol. 1983;4: 407-442.
16. Sinclair SR, Fawcett JW, Dunnett SB. Dopamine cells in nigral grafts differentiate prior to implantation. Eur J Neurosci. 1999;11: 4341-4348.
17. Björklund A, Schmidt RH, Stenevi U. Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra. Cell Tissue Res. 1980;212: 39-45.
18. Dunnett SB, Torres EM, Gates MA, Fricker-Gates RA. Neural transplantation. In: Tatlisumak T, Fisher M, eds. Handbook of Experimental Neurology: Methods and Techniques in Animal Research. Cambridge, England: Cambridge University Press; 2006;269-307.
19. Schmidt RH, Björklund A, Stenevi U. Intracerebral grafting of dissociated CNS tissue suspensions: a new approach for neuronal transplantation to deep brain sites. Brain Res. 1981;218: 347-356.
20. Brundin P, Barbin G, Strecker RE, Isacson O, Prochiantz A, Björklund A. Survival and function of dissociated rat dopamine neurons grafted at different developmental stages or after being cultured in vitro. Dev Brain Res. 1988;467: 233-243.
21. Torres EM, Monville C, Lowenstein PR, Castro MG, Dunnett SB. Delivery of the sonic hedgehog or glial derived neurotrophic factor to dopaminerich grafts in a rat model of Parkinson's disease using adenoviral vectors. Increased yield of dopamine cells is dependent on embryonic donor age. Brain Res Bull. 2005;68: 31-41.
22. Torres EM, Monville C, Gates MA, Bagga V, Dunnett SB. Improved survival of young donor age dopamine grafts in a rat model of Parkinson's disease. Neuroscience. 2007;146: 1606-1617.
23. Björklund A, Stenevi U, Schmidt RH, Dunnett SB, Gage FH. Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites. Acta Physiol Scand Suppl. 1983;522: 9-18.
24. Doucet G, Brundin P, Descarries L, Björklund A. Effect of prior dopamine denervation on survival and fiber outgrowth from intrastriatal fetal mesencephalic grafts. Eur J Neurosci. 1990;2: 279-290.
25. Manier M, Abrous DN, Feuerstein C, Le Moal M, Herman JP. Increase of striatal methionin enkephalin content following lesion of the nigrostriatal dopaminergic pathway in adult rats and reversal following the implantation of embryonic dopaminergic neuron--a quantitative immunohistochemical analysis. Neuroscience. 1991;42: 427-439.
26. Nikkhah G, Cunningham MG, Jödicke A, Knappe U, Björklund A. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat parkinson model. Brain Res. 1994;633: 133-143.
27. Winkler C, Bentlage C, Nikkhah G, Samii M, Björklund A. Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants. Exp Neurol. 1999;155: 165-186.
28. Hudson JL, Bickford P, Johansson M, Hoffer BJ, Strömberg I. Target and neurotransmitter specificity of fetal central nervous system transplants: importance for functional reinnervation. J Neurosci. 1994;14: 283-290.
29. Zuddas A, Corsini GU, Barker JL, Kopin IJ, Di Porzio U. Specific reinnervation of lesioned mouse striatum by grafted mesencephalic dopaminergic neurons. Eur J Neurosci. 1991;3: 72-85.
30. Dahlström A, Fuxe K. Evidence for the existence of monoaminecontaining neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand Suppl. 1964;232: 1-55.
31. Haque NSK, Borghesani P, Isacson O. Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons. Cell Transplant. 1997;6: 239-248.
32. Schultzberg M, Dunnett SB, Björklund A, et al. Dopamine and cholecystokinin immunoreactive neurons in mesencephalic grafts reinnervating the neostriatum: evidence for selective growth regulation. Neuroscience. 1984;12: 17-32.
33. Thompson L, Barraud P, Andersson E, Kirik D, Björklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci. 2005;25: 6467-6477.
34. Sawamoto K, Nakao N, Kakishita K, et al. Generation of dopaminergic neurons in the adult brain from mesencephalic precursor cells labeled with a nestin-GFP transgene. J Neurosci. 2001;21: 3895-3903.
35. Arbuthnott GW, Dunnett SB, MacLeod N. The electrophysiological properties of single units in mesencephalic transplants in rat brain. Neurosci Lett. 1985;57: 205-210.
36. Doucet G, Murata Y, Brundin P, et al. Host afferents into intrastriatal transplants of fetal ventral mesencephalon. Exp Neurol. 1989;106: 1-9.
37. Fisher LJ, Young SJ, Tepper JM, Groves PM, Gage FH. Electrophysiological characteristics of cells within mesencephalon suspension grafts. Neuroscience. 1991;40: 109-122.
38. Freund TF, Bolam JP, Björklund A, et al. Efferent synaptic connections of grafted dopaminergic-neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study. J Neurosci. 1985;5: 603-616.
39. Mahalik TJ, Finger TE, Strömberg I, Olson L. Substantia nigra transplants into denervated striatum of the rat: ultrastructure of graft and host interconnections. J Comp Neurol. 1985;240: 60-70.
40. Rioux L, Gaudin DP, Bui LK, Grégoire L, DiPaolo T, Bédard PJ. Correlation of functional recovery after a 6-hydroxydopamine lesion with survival of grafted fetal neurons and release of dopamine in the striatum of the rat. Neuroscience. 1991;40: 123-131.
41. Strecker RE, Sharp T, Brundin P, Zetterström T, Ungerstedt U, Björklund A. Auto-regulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience. 1987;22: 169-178.
42. Cenci MA, Kalén P, Mandel RJ, Björklund A. Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res. 1992;581: 217-228.
43. Cenci MA, Kalén P, Mandel RJ, Wictorin K, Björklund A. Dopaminergic transplants normalize amphetamine-and apomorphine-induced fos expression in the 6-hydroxydopamine-lesioned striatum. Neuroscience. 1992;46: 943-957.
44. Cenci MA, Campbell K, Björklund A. Glutamic acid decarboxylase gene expression in the dopamine-denervated striatum: effects of intrastriatal fetal nigral transplants or chronic apomorphine treatment. Mol Brain Res. 1997;48: 149-155.
45. Chritin M, Savasta M, Mennicken F, et al. Intrastriatal dopamine-rich implants reverse the increase of dopamine D2 receptor mRNA levels caused by lesion of the nigrostriatal pathway: a quantitative in situ hybridization study. Eur J Neurosci. 1992;4: 663-672.
46. Dawson TM, Dawson VL, Gage FH, Fisher LJ, Hunt MA, Wamsley JK. Functional recovery of supersensitive dopamine receptors after intrastriatal grafts of fetal substantia nigra. Exp Neurol. 1991;111: 282-292.
47. Savasta M, Mennicken F, Chritin M, et al. Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats: an autoradiographic study. Neuroscience. 1992;46: 729-738.
48. Sirinathsinghji DJS, Dunnett SB. Increased proenkephalin mRNA levels in the rat neostriatum following lesion of the ipsilateral nigrostriatal dopamine pathway with 1-methyl-4-phenylpyridinium ion (MPP+): reversal by embryonic nigral dopamine grafts. Mol Brain Res. 1991;9: 263-269.
49. Bentlage C, Nikkhah G, Cunningham MG, Björklund A. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host. Exp Neurol. 1999;159: 177-190.
50. Mendez I, Sadi D, Hong M. Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants. J Neurosci. 1996;16: 7216-7227.
51. Mukhida K, Baker KA, Sadi D, Mendez I. Enhancement of sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, intranigral, and intrasubthalamic nucleus dopaminergic transplants. J Neurosci. 2001;21: 3521-3530.
52. Nikkhah G, Cunningham MG, Cenci MA, McKay RD, Björklund A. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. I. Evidence for anatomical reconstruction of the nigrostriatal pathway. J Neurosci. 1995;15: 3548-3561.
53. Isacson O, Deacon TW, Pakzaban P, Galpern WR, Dinsmore J, Burns LH. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med. 1995;1: 1189-1194.
54. Wictorin K, Brundin P, Gustavii B, Lindvall O, Björklund A. Reformation of long axon pathways in adult rat central nervous system by human forebrain neuroblasts. Nature. 1990;347: 556-558.
55. Wictorin K, Lagenaur CF, Lund RD, Björklund A. Efferent projections to the host brain from intrastriatal striatal mouse-to-rat grafts: time course and tissue-type specificity as revealed by a mouse specific neuronal marker. Eur J Neurosci. 1991;3: 86-101.
56. Isacson O, Deacon TW. Specific axon guidance factors persist in the adult brain as demonstrated by pig neuroblasts transplanted to the rat. Neuroscience. 1996;75: 827-837.
57. Gaillard A, Prestoz L, Dumartin B, et al. Reestablishment of damaged adult motor pathways by grafted embryonic cortical neurons. Nat Neurosci. 2007;10: 1294-1299.
58. Davies SJA, Field PM, Raisman G. Long interfascicular axon growth from embryonic neurons transplanted into adult myelinated tracts. J Neurosci. 1994;14: 1596-1612.
59. Björklund A, Nornes H, Gage FH. Cell suspension grafts of noradrenergic locus coeruleus neurons in rat hippocampus and spinal cord--reinnervation and transmitter turnover. Neuroscience. 1986;18: 685-698.
60. Li Y, Raisman G. Long axon growth from embryonic neurons transplanted into myelinated tracts of the adult rat spinal cord. Brain Res. 1993;629: 115-127.
61. Wictorin K, Brundin P, Sauer H, Lindvall O, Björklund A. Long distance directed axonal growth from human dopaminergic mesencephalic neuroblasts implanted along the nigrostriatal pathway in 6-hydroxydopamine lesioned adult rats. J Comp Neurol. 1992;323: 475-494.
62. Thompson LH, Grealish S, Kirik D, Björklund A. Reconstruction of the nigro-striatal dopamine pathway in the adult mouse brain J Neurosci. 2009; in press.
63. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand Supp. 1971;367: 49-68.
64. Dunnett SB, Björklund A, Schmidt RH, Stenevi U, Iversen SD. Intracerebral grafting of neuronal cell suspensions. IV. Behavioral recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol Scand Suppl. 1983;522: 29-37.
65. Dunnett SB, Hernandez TD, Summerfield A, Jones GH, Arbuthnott GW. Graft-derived recovery from 6-OHDA lesions: specificity of ventral mesencephalic graft tissues. Exp Brain Res. 1988;71: 411-424.
66. Schmidt RH, Björklund A, Stenevi U, Dunnett SB, Gage FH. Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. Acta Physiol Scand Suppl. 1983;522: 19-28.
67. Brundin P, Widner H, Nilsson OG, Strecker RE, Björklund A. Intracerebral xenografts of dopamine neurons: the role of immunosuppression and the blood-brain barrier. Exp Brain Res. 1989;75: 195-207.
68. Björklund A, Dunnett SB, Stenevi U, Lewis ME, Iversen SD. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 1980;199: 307-333.
69. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamineinduced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971;367: 69-93.
70. Freed WJ, Ko GN, Niehoff DL, et al. Normalization of spiroperidol binding in the denervated rat striatum by homologous grafts of substantia nigra. Science. 1983;222: 937-939.
71. Bing G, Notter MFD, Hansen JT, Gash DM. Comparison of adrenal medullary, carotid body and PC12 cell grafts in 6-OHDA lesioned rats. Brain Res Bull. 1988;20: 399-406.
72. Brown VJ, Dunnett SB. Comparison of adrenal and fetal nigral grafts on drug-induced rotation in rats with 6-OHDA lesions. Exp Brain Res. 1989;78: 214-218.
73. Hargraves RW, Freed WJ. Chronic intrastriatal dopamine infusions in rats with unilateral lesions of the substantia nigra. Life Sci. 1987;40: 959-966.
74. Kirik D, Georgievska B, Burger C, et al. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAVmediated gene transfer. Proc Natl Acad Sci USA. 2002;99: 4708-4713.
75. Hefti F, Melamed E, Sahakian BJ, Wurtman RJ. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effects of amphetamine, apomorphine, and DOPA. Pharmacol Biochem Behav. 1980;12: 185-188.
76. Sauer H, Brundin P. Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. Rest Neurol Neurosci. 1991;2: 123-135.
77. Freeman TB, Sanberg PR, Nauert GM, et al. The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts. Cell Transplant. 1995;4: 141-154.
78. Heim RC, Willingham G, Freed WJ. A comparison of solid intraventricular and dissociated intraparenchymal fetal substantia nigra grafts in a rat model of Parkinson's disease: impaired graft survival is associated with high baseline rotational behavior. Exp Neurol. 1993;122: 5-15.
79. Leigh K, Elisevich K, Rogers KA. Vascularization and microvascular permeability in solid versus cell-suspension embryonic neural grafts. J Neurosurg. 1994;81: 272-283.
80. Nikkhah G, Rosenthal C, Hedrich HJ, Samii M. Differences in acquisition and full performance in skilled forelimb use as measured by the "staircase test" in five rat strains. Behav Brain Res. 1998;92: 85-95.
81. Galpern WR, Burns LH, Deacon TW, Dinsmore J, Isacson O. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. Exp Neurol. 1996;140: 1-13.
82. Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci. 1999;11: 1554-1566.
83. Wilby M, Sinclair SR, Muir EM, et al. A GDNF-secreting clone of the Schwann cell line SCTM41 enhances survival and fibre outgrowth from embryonic nigral neurones grafted to the striatum and the lesioned substantia nigra. J Neurosci. 1999;19: 2301-2312.
84. Castilho RF, Hansson O, Brundin P. Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. Prog Brain Res. 2000;127: 203-231.
85. Nakao N, Frodl EM, Duan WM, Widner H, Brundin P. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci USA. 1994;91: 12408-12412.
86. Barker RA, Dunnett SB. Ibotenic acid lesions of the striatum reduce druginduced rotation in the 6-hydroxydopamine-lesioned rat. Exp Brain Res. 1994;101: 365-374.
87. Marshall JF, Levitan D, Stricker EM. Activation-induced restoration of sensorimotor functions in rats with dopamine-depleting brain lesions. J Comp Physiol Psychol. 1976;90: 536-546.
88. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971;367: 96-122.
89. Zigmond MJ, Stricker EM. Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in rats. Science. 1972;177: 1211-1214.
90. Dunnett SB, Björklund A, Stenevi U, Iversen SD. Behavioral recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. 2. Bilateral lesions. Brain Res. 1981;229: 457-470.
91. Dunnett SB, Björklund A, Stenevi U, Iversen SD. Grafts of embryonic substantia nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway. Brain Res. 1981;229: 209-217.
92. Dunnett SB, Björklund A, Schmidt RH, Stenevi U, Iversen SD. Intracerebral grafting of neuronal cell suspensions. V. Behavioral recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. Acta Physiol Scand Suppl. 1983;522: 39-47.
93. Brundin P, Strecker RE, Londos E, Björklund A. Dopamine neurons grafted unilaterally to the nucleus accumbens affect drug-induced circling and locomotion. Exp Brain Res. 1987;69: 183-194.
94. Dunnett SB, Whishaw IQ, Rogers DC, Jones GH. Dopamine-rich grafts ameliorate whole body motor asymmetry and sensory neglect but not independent limb use in rats with 6-hydroxydopamine lesions. Brain Res. 1987;415: 63-78.
95. Montoya CP, Astell S, Dunnett SB. Effects of nigral and striatal grafts on skilled forelimb use in the rat. Prog Brain Res. 1990;82: 459-466.
96. Abrous DN, Torres EM, Dunnett SB. Dopaminergic grafts implanted into the neonatal or adult striatum: comparative effects on rotation and paw reaching deficits induced by subsequent unilateral nigrostriatal lesions in adulthood. Neuroscience. 1993;54: 657-668.
97. Nikkhah G, Cunningham MG, McKay R, Björklund A. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. II. Transplant-induced behavioral recovery. J Neurosci. 1995;15: 3562-3570.
98. Dunnett SB, Rogers DC, Richards SJ. Nigrostriatal reconstruction after 6-OHDA lesions in rats: combination of dopamine-rich nigral grafts and nigrostriatal bridge grafts. Exp Brain Res. 1989;75: 523-535.
99. Brecknell JE, Haque NS, Du JS, et al. Functional and anatomical reconstruction of the 6-hydroxydopamine lesioned nigrostriatal system of the adult rat. Neuroscience. 1996;71: 913-925.
100. Kirik D, Winkler C, Björklund A. Growth and functional efficacy of intrastriatal nigral transplants depends on the extent of nigrostriatal degeneration. J Neurosci. 2001;21: 2889-2896.
101. Dowd E, Monville C, Torres EM, Dunnett SB. The corridor task: a simple test of lateralised response selection and neglect sensitive to unilateral dopamine deafferentation and graft-derived replacement in the striatum. Brain Res Bull. 2005;68: 24-30.
102. Breysse N, Carlsson T, Winkler C, Björklund A, Kirik D. The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian rats is reduced with advancing disease. J Neurosci. 2007;27: 5849-5856.
103. Nikkhah G, Bentlage C, Cunningham MG, Björklund A. Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. J Neurosci. 1994;14: 3449-3461.
104. Baker KA, Sadi D, Hong M, Mendez I. Simultaneous intrastriatal and intranigral dopaminergic grafts in the Parkinsonian rat model: role of the intranigral graft. J Comp Neurol. 2000;426: 106-116.
105. Winkler C, Kirik D, Björklund A, Dunnett SB. Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Prog Brain Res. 2000;127: 233-265.
106. Rozas G, Guerra MJ, Labandeira-García JL. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Prot. 1997;2: 75-84.
107. Schallert T, Tillerson JL. Intervention strategies for degeneration of dopamine neurons in Parkinsonism: optimizing behavioral assessment of outcome. In: Emerich DF, Dean RL, Sanberg PR, eds. Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic. Totowa, NJ: Humana Press; 2000;131-151.
108. Cenci MA, Lundblad M. Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease. In: LeDoux M, ed. Animal Models of Movement Disorders. Amsterdam, the Netherlands: Elsevier; 2005;193-209.
109. Olsson M, Nikkhah G, Bentlage C, Björklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci. 1995;15: 3863-3875.
110. Rozas G, Labandeira-García JL. Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res. 1997;749: 188-199.
111. Nikkhah G, Rosenthal C, Falkenstein G, Samii M. Dopaminergic graftinduced long-term recovery of complex sensorimotor behaviors in a rat model of Parkinson's disease. Zentralbl Neurochi.r 1998;59: 97-103.
112. Roedter A, Winkler C, Samii M, Nikkhah G. Complex sensorimotor behavioral changes after terminal striatal 6-OHDA lesion and transplantation of dopaminergic embryonic micrografts. Cell Transplant. 2001;9: 197-214.
113. Torres EM, Dowd E, Dunnett SB. Recovery of functional deficits following early donor age (E12) ventral mesencephalic grafts in a rat model of Parkinson's disease. Neuroscience. 2008;154: 631-640.
114. Sass KJ, Buchanan CP, Westerveld M, et al. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. Arch Neurol. 1995;52: 680-686.
115. Leroy A, Michelet D, Mahieux F, et al. [Neuropsychological testing of 5 patients with Parkinson's disease before and after neuron graft]. Rev Neurol (Paris). 1996;152: 158-164.
116. Marshall JF, Richardson JS, Teitelbaum P. Nigrostriatal bundle damage and the lateral hypothalamic syndrome. J Comp Physiol Psychol. 1974;87: 808-830.
117. Simon H. Dopaminergic A10 neurons and frontal system. J Physiol (Paris). 1981;77: 81-95.
118. Dunnett SB, Iversen SD. Neurotoxic lesions of ventrolateral but not anteromedial neostriatum in rats impair differential reinforcement of low rates (DRL) performance. Behav Brain Res. 1982;6: 213-226.
119. Zigmond MJ, Stricker EM. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science. 1973;182: 717-720.
120. Mishkin M, Malamut B, Bachevalier J. Memories and habits: two neural systems. In: Lynch G, McGaugh JL, Weinberger NM, eds. Neurobiology of Learning and Memory. New York, NY: Guilford Press; 1984: 65-77.
121. Gaffan D. Memory, action and the corpus striatum--current developments in the memory-habit distinction. Semin Neurosci. 1996;8: 33-38.
122. White NM. Mnemonic functions of the basal ganglia. Curr Opin Neurobiol. 1997;7: 164-169.
123. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36: 241-263.
124. Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007;30: 211-219.
125. Carli M, Evenden JL, Robbins TW. Depletion of unilateral striatal dopamine impairs initiation of contralateral actions and not sensory attention. Nature. 1985;313: 679-682.
126. Dowd E, Dunnett SB. Deficits in a lateralised associative learning task in dopamine-depleted rats, with selective recovery by dopamine-rich transplants. Eur J Neurosci. 2004;20: 1953-1959.
127. Fray PJ, Dunnett SB, Iversen SD, Björklund A, Stenevi U. Nigral transplants reinnervating the dopamine-depleted neostriatum can sustain intracranial self-stimulation. Science. 1983;219: 416-419.
128. Shimizu K, Tsuda N, Okamoto Y, et al. Transplant-induced recovery from 6-OHDA lesions of the nigrostriatal dopamine neurones in mice. Acta Neurochir Suppl. 1988;43: 149-153.
129. Brundin P, Isacson O, Gage FH, Prochiantz A, Björklund A. The rotating 6-hydroxydopamine lesioned mouse as a model for assessing functional effects of neuronal grafting. Brain Res. 1986;366: 346-349.
130. Witt TC, Triarhou LC. Transplantation of mesencephalic cell suspensions from wild-type and heterozygous weaver mice into the denervated striatum--assessing the role of graft-derived dopaminergic dendrites in the recovery of function. Cell Transplant. 1995;4: 323-333.
131. Di Porzio U, Zuddas A. Embryonic dopaminergic neuron transplants in MPTP lesioned mouse striatum. Neurochem Int. 1992;20(suppl): 309S-320S.
132. Bohn MC, Kanuicki M. Bilateral recovery of striatal dopamine after unilateral adrenal grafting into the striatum of the 1-methyl-4-(2'methylphenyl)-1,2,3,6-tetrahydropyridine (2'CH3-MPTP)-treated mice. J Neurosci Res. 1990;25: 281-286.
133. Bohn MC, Cupit L, Marciano F, Gash DM. Adrenal grafts enhance recovery of striatal dopaminergic fibers. Science. 1987;237: 913-916.
134. Kong XY, Cai Z, Pan L, et al. Transplantation of human amniotic cells exerts neuroprotection in MPTP-induced Parkinson disease mice. Brain Res. 2008;1205: 108-115.
135. Liker MA, Petzinger GA, Nixon K, McNeill T, Jakowec MW. Human neural stem cell transplantation in the MPTP-lesioned mouse. Brain Res. 2003;971: 168-177.
136. Ourednik J, Ourednik V, Lynch WP, Schachner M, Snyder EY. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol. 2002;20: 1103-1110.
137. Sedelis M, Schwarting RK, Huston JP. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res. 2001;125: 109-125.
138. Triarhou LC. Dopaminergic Neuron Transplantation in the Weaver Mouse Model of Parkinson's Disease. New York, NY: Kluwer Academic; 2002.
139. Triarhou LC, Low WC, Ghetti B. Transplantation of ventral mesencephalic anlagen to hosts with genetic nigrostriatal dopamine deficiency. Proc Natl Acad Sci USA. 1986;83: 8789-8793.
140. Triarhou LC, Low WC, Norton J, Ghetti B. Reinstatement of synaptic connectivity in the striatum of weaver mutant mice following transplantation of ventral mesencephalic anlagen. J Neurocytol. 1988;17: 233-243.
141. Triarhou LC, Norton J, Hingtgen JN. Amelioration of the behavioral phenotype in weaver mutant mice through bilateral intrastriatal grafting of fetal dopamine cells. Exp Brain Res. 1995;104: 191-198.
142. Sorensen AT, Thompson L, Kirik D, Björklund A, Lindvall O, Kokaia M. Functional properties and synaptic integration of genetically labelled dopaminergic neurons in intrastriatal grafts. Eur J Neurosci. 2005;21: 2793-2799.
143. Quintana JG, Lopez-Colberg I, Cunningham LA. Use of GFAP-lacZ transgenic mice to determine astrocyte fate in grafts of embryonic ventral midbrain. Dev Brain Res. 1998;105: 147-151.
144. Nakao N, Frodl EM, Widner H, et al. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nat Med. 1995;1: 226-231.
145. Hedlund E, Pruszak J, Lardaro T, et al. Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells. 2008;26: 1526-1536.
146. Carlsson T, Winkler C, Lundblad M, Cenci MA, Björklund A, Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis. 2006;21: 657-668.
147. Lane EL, Winkler C, Brundin P, Cenci MA. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol Dis. 2006;22: 334-346.
148. Lee CS, Cenci MA, Schulzer M, Björklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain. 2000;123: 1365-1379.
149. Steece-Collier K, Collier TJ, Danielson PD, Kurlan R, Yurek DM, Sladek JR. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats. Mov Disord. 2003;18: 1442-1454.
150. Carlsson T, Carta M, Munoz A, et al. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2008;132: 319-335.
151. Defer GL, Gény C, Ricolfi F, et al. Long-term outcome of unilaterally transplanted Parkinsonian patients. 1. Clinical approach. Brain. 1996;119: 41-50.
152. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol. 1999;56: 179-187.
153. Brundin P, Pogarell O, Hagell P, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain. 2000;123: 1380-1390.
154. Hagell P, Schrag A, Piccini P, et al. Sequential bilateral transplantation in Parkinson's disease--effects of the second graft. Brain. 1999;122: 1121-1132.
155. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344: 710-719.
156. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003;54: 403-414.
157. Olanow CW, Gracies JM, Goetz CG, et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009; 24: 335-343.
158. Ma YL, Feigin A, Dhawan V, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol. 2002;52: 628-634.
159. Maries E, Kordower JH, Chu Y, et al. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis. 2006;21: 165-180.
160. Lane EL, Dunnett SB. Animal models of Parkinson's disease and l-dopa induced dyskinesia. How close are we to the clinic? Psychopharmacology (Berl). 2008;199: 303-312.
161. Carlsson T, Carta M, Winkler C, Björklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci. 2007;27: 8011-8022.
162. Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007;130: 1819-1833.
163. Freed WJ. Repairing neuronal circuits with brain grafts: where can brain grafts be used as a therapy? Neurobiol Aging. 1985;6: 153-156.
164. Björklund A, Lindvall O, Isacson O, et al. Mechanisms of action of intracerebral neural implants--studies on nigral and striatal grafts to the lesioned striatum. Trends Neurosci. 1987;10: 509-516.
165. Gage FH, Buzsaki G. CNS grafting: potential mechanisms of action. In: Seil FJ, ed. Neural Regeneration and Transplantation. New York, NY: Alan R. Liss; 1989;211-226.
166. Dunnett SB. Cell replacement therapy: mechanisms of functional recovery. In: Squire LR, ed. New Encyclopedia of Neuroscience. Amsterdam, the Netherlands: Elsevier; 2009; pp 643-647.
167. Krauss JK, Jankovic J, Grossman RG. Surgery for Parkinson's Disease and Movement Disorders. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001.
168. Perlmutter JS, Mink JW. Deep brain stimulation. Annu Rev Neurosci. 2006;29: 229-257.
169. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12: 366-375.
170. Meyers R. Surgical experiments in therapy of certain "extrapyramidal" diseases: current evaluation. Acta Psychiatr Neurol Suppl 1951;67: 1-42.
171. Johnston RE, Becker JB. Behavioral changes associated with grafts of embryonic ventral mesencephalon tissue into the striatum and/or substantia nigra in a rat model of Parkinson's disease. Behav Brain Res. 1999;104: 179-187.
172. Forni C, Brundin P, Strecker RE, Elganouni S, Björklund A, Nieoullon A. Time-course of recovery of dopamine neuron activity during reinnervation of the denervated striatum by fetal mesencephalic grafts as assessed by in vivo voltammetry. Exp Brain Res. 1989;76: 75-87.
173. Strömberg I, Adams C, Bygdeman M, Hoffer B, Boyson S, Humpel C. Long-term effects of human-to-rat mesencephalic xenografts on rotational behavior, striatal dopamine receptor binding, and mRNA levels. Brain Res Bull. 1995;38: 221-233.
174. McRae-Degueurce A, Hjorth S, Dillon DL, Mason DW, Tice TR. Implantable microencapsulated dopamine (DA): a new approach for slow release DA delivery into brain tissue. Neurosci Lett. 1988;92: 303-309.
175. Freed WJ, Morihisa JM, Spoor E, et al. Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behavior. Nature. 1981;292: 351-352.
176. Azzouz M, Martin-Rendon E, Barber RD, et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci. 2002;22: 10302-10312.
177. Gage FH, Björklund A. Trophic and growth-regulating mechanisms in the central nervous system monitored by intracerebral neural transplants. Ciba Found Symp. 1987;126: 143-159.
178. Strömberg I, Wetmore CJ, Ebendal T, Ernfors P, Persson H, Olson L. Rescue of basal forebrain cholinergic neurons after implantation of genetically modified cells producing recombinant NGF. J Neurosci Res. 1990;25: 405-411.
179. Raymon HK, Thode S, Gage FH. Application of ex vivo gene therapy in the treatment of Parkinson's disease. Exp Neurol. 1997;144: 82-91.
180. Olson L, Ayer-LeLievre C, Ebendal T, et al. Grafts, growth factors and grafts that make growth factors. Prog Brain Res. 1990;82: 55-66.
181. Dunnett SB, Mayer E. Neural grafts, growth factors and trophic mechanisms of recovery. In: Hunter AJ, Clarke M, eds. Neurodegeneration. New York, NY: Academic Press; 1992: 183-217.
182. Brundin P, Karlsson J, Emgård M, et al. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant. 2000;9: 179-195.
183. Mayer E, Fawcett JW, Dunnett SB. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons. II. Effects on neural transplants in vivo. Neuroscience. 1993;56: 389-398.
184. Strömberg I, Björklund L, Johansson M, et al. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol. 1993;124: 401-412.
185. Rosenblad C, Martinez-Serrano A, Björklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience. 1996;75: 979-985.
186. Sinclair SR, Svendsen CN, Torres EM, Martin D, Fawcett JW, Dunnett SB. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport. 1996;7: 2547-2552.
187. Hansson O, Castilho RF, Schierle GSK, et al. Additive effects of caspase inhibitor and lazaroid on the survival of transplanted rat and human embryonic dopamine neurons. Exp Neurol. 2000;164: 102-111.
188. Sánchez-Capelo A, Corti O, Mallet J. Adenovirus-mediated overexpression of TGFb1 in the striatum decreases dopaminergic cell survival in embryonic nigral grafts. Neuroreport. 1999;10: 2169-2173.
189. Takayama H, Ray J, Raymon HK, et al. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nat Med. 1995;1: 53-58.
190. Barkats M, Nakao N, Grasbon-Frodl EM, et al. Intrastriatal grafts of embryonic mesencephalic rat neurons genetically modified using an adenovirus encoding human Cu/Zn superoxide dismutase. Neuroscience. 1997;78: 703-713.
191. Ostenfeld T, Tai YT, Martin P, Déglon N, Aebischer P, Svendsen CN. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res. 2002;69: 955-965.
192. Connor B, Kozlowski DA, Unnerstall JR, et al. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp Neurol. 2001;169: 83-95.
193. Georgievska B, Kirik D, Rosenblad C, Lundberg C, Björklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport. 2002;13: 75-82.
194. Patel NK, Bunnage M, Plaha P, Svendsen CN, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol. 2005;57: 298-302.
195. Patel NK, Gill SS. GDNF delivery for Parkinson's disease. Acta Neurochir Suppl. 2007;97: 135-154.
196. Brundin P, Isacson O, Gage FH, Björklund A. Intrastriatal grafting of dopamine-containing neuronal cell suspensions: effects of mixing with target or non-target cells. Dev Brain Res. 1986;24: 77-84.
197. Jaeger CB. Axon terminal clustering in nigrostriatal double grafts. Dev Brain Res. 1986;24: 309-314.
198. de Beaurepaire R, Freed WJ. Embryonic substantia nigra grafts innervate embryonic striatal co-grafts in preference to mature host striatum. Exp Neurol. 1987;95: 448-454.
199. Yurek DM. Intranigral transplants of fetal ventral mesencephalic tissue attenuate D1-agonist-induced rotational behavior. Exp Neurol. 1997;143: 1-9.
200. Palmer MR, Granholm AC, van Horne CG, et al. Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6-OHDA-lesioned rats. Brain Res. 2001;890: 86-99.
201. David S, Aguayo AJ. Axonal elongation into peripheral nervous system "bridges" after central nervous system injury in adult rats. Science. 1981;214: 931-933.
202. Olson L. Regeneration in the adult central nervous system: experimental repair strategies. Nat Med. 1997;3: 1329-1335.
203. Aguayo AJ, Björklund A, Stenevi U, Carlstedt T. Fetal mesencephalic neurons survive and extend long axons across peripheral nervous system grafts inserted into the adult rat striatum. Neurosci Lett. 1984;45: 53-58.
204. Gage FH, Stenevi U, Carlstedt T, Foster G, Björklund A, Aguayo AJ. Anatomical and functional consequences of grafting mesencephalic neurons into a peripheral nerve bridge connected to the denervated striatum. Exp Brain Res. 1985;60: 584-589.
205. Zhou FC, Chiang YH, Wang Y. Constructing a new nigrostriatal pathway in the Parkinsonian model with bridged neural transplantation in substantia nigra. J Neurosci. 1996;16: 6965-6974.
206. Christophersen NS, Correia AS, Roybon L, Li JY, Brundin P. Developing novel stem cell sources for transplantation in Parkinson's disease. In: Davis Sanberg C, Sanberg PR, eds. Cell Therapy, Stem Cells, and Brain Repair. Totowa, NJ: Humana Press; 2006: 31-59.
207. Espejo EF, Montoro RJ, Armengol JA, López-Barneo J. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron. 1998;20: 197-206.
208. Brundin P, Duan WM, Sauer H. Functional effects of mesencephalic dopamine neurons and adrenal chromaffin cells grafted to the rodent striatum. In: Dunnett SB, Björklund A, eds. Functional Neural Transplantation. New York, NY: Raven Press; 1994: 9-46.
209. Quinn NP. The clinical application of cell grafting techniques in patients with Parkinson's disease. Prog Brain Res. 1990;82: 619-625.
210. Goetz CG, Stebbins GT, Klawans HL, et al. United Parkinson Foundation neurotransplantation registry on adrenal medullary transplants: presurgical, and 1-year and 2-year follow-up. Neurology. 1991;41: 1719-1722.
211. Adams FS, La Rosa FG, Kumar S, et al. Characterization and transplantation of two neuronal cell lines with dopaminergic properties. Neurochem Res. 1996;21: 619-627.
212. Horellou P, Brundin P, Kalén P, Mallet J, Björklund A. In vivo release of DOPA and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron. 1990;5: 393-402.
213. Uchida K, Takamatsu K, Kaneda N, et al. Synthesis of L-3,4-dihydroxyphenylalanine by tryosine hydroxylase cDNA-transfected C6 cells: application for intracerebral grafting. J Neurochem. 1989;53: 728-732.
214. Jaeger CB. Immunocytochemical study of PC12 cells grafted to the brain of immature rats. Exp Brain Res. 1985;59: 615-624.
215. Folkerth RD, Durso R. Survival and proliferation of non-neural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology. 1996;46: 1219-1225.
216. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990;249: 1436-1438.
217. Limousin P, Pollak P, Benazzouz A, et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345: 91-95.
218. Isacson O, Frim DM, Galpern WR, Tatter SB, Breakefield XO, Schumacher JM. Cell-mediated delivery of neurotrophic factors and neuroprotection in the neostriatum and substantia nigra. Rest Neurol Neurosci. 1995;8: 59-61.
219. Åkerud P, Canals JM, Snyder EY, Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci. 2001;21: 8108-8118.
220. Bankiewicz KS, Mandel RJ, Sofroniew MV. Trophism, transplantation, and animal models of Parkinson's disease. Exp Neurol. 1993;124: 140-149.
221. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 1990;247: 574-577.
222. Barker RA, Ratcliffe E, Richards A, Dunnett SB. Fetal porcine dopaminergic cell survival in vitro and its relationship to embryonic age. Cell Transplant. 1999;8: 593-599.
223. Schumacher JM, Ellias SA, Palmer EP, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology. 2000;54: 1042-1050.
224. Backlund EO, Granberg PO, Hamberger B, et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg. 1985;62: 169-173.
225. Arjona V, Mínguez-Castellanos A, Montoro RJ, et al. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery. 2003;53: 321-328.
226. Wolff JA, Fisher LJ, Xu L, et al. Grafting fibroblasts genetically modified to produce l-DOPA in a rat model of Parkinson disease. Proc Natl Acad Sci USA. 1989;86: 9011-9014.
227. Svendsen CN, Clarke DJ, Rosser AE, Dunnett SB. Survival and differentiation of rat and human EGF responsive precursor cells following grafting into the lesioned adult CNS. Exp Neurol. 1996;137: 376-388.
228. Studer L, Tabar V, McKay RDG. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci. 1998;1: 290-295.
229. Björklund L, Sánchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA. 2002;99: 2344-2349.
230. Kim JH, Auerbach JM, Rodriguez-Gomez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418: 50-56.
231. Dziewczapolski G, Lie DC, Ray J, Gage FH, Shults CW. Survival and differentiation of adult rat-derived neural progenitor cells transplanted to the striatum of hemiparkinsonian rats. Exp Neurol. 2003;183: 653-664.
232. Ende N, Chen R. Parkinson's disease mice and human umbilical cord blood. J Med. 2002;33: 173-180.
233. Cenci MA, Kalén P, Duan WM, Björklund A. Transmitter release from transplants of fetal ventral mesencephalon and locus coeruleus in the rat frontal cortex and nucleus accumbens: effects of pharmacological and behavioural activating stimuli. Brain Res. 1994;641: 225-248.